| __timestamp | Amneal Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 785623000 | 28203205 |
| Thursday, January 1, 2015 | 866280000 | 99892000 |
| Friday, January 1, 2016 | 1018225000 | 133591000 |
| Sunday, January 1, 2017 | 1033654000 | 154937000 |
| Monday, January 1, 2018 | 1662991000 | 164246000 |
| Tuesday, January 1, 2019 | 1626373000 | 175338000 |
| Wednesday, January 1, 2020 | 1992523000 | 198321000 |
| Friday, January 1, 2021 | 2093669000 | 227490000 |
| Saturday, January 1, 2022 | 2212304000 | 212018000 |
| Sunday, January 1, 2023 | 2393607000 | 145238000 |
Data in motion
In the competitive landscape of pharmaceuticals, Amneal Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have shown distinct revenue trajectories over the past decade. From 2014 to 2023, Amneal's revenue surged by over 200%, peaking at approximately $2.4 billion in 2023. This growth reflects a robust expansion strategy and successful product launches. In contrast, Travere's revenue, while growing, reached a more modest peak of around $227 million in 2021, before declining to $145 million in 2023. This represents a 400% increase from its 2014 figures, showcasing its niche focus and steady market penetration. The data highlights Amneal's dominance in scale, while Travere's growth underscores its strategic positioning in specialized markets. As the pharmaceutical industry evolves, these companies exemplify diverse paths to success, driven by innovation and market adaptation.
Breaking Down Revenue Trends: Amgen Inc. vs Travere Therapeutics, Inc.
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Examining Key Revenue Metrics
Who Generates More Revenue? Gilead Sciences, Inc. or Travere Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. and Amneal Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Who Generates More Revenue? Alnylam Pharmaceuticals, Inc. or Travere Therapeutics, Inc.
Exelixis, Inc. and Amneal Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis
Revenue Showdown: Alkermes plc vs Travere Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs MorphoSys AG: Examining Key Revenue Metrics
Revenue Insights: Amneal Pharmaceuticals, Inc. and Novavax, Inc. Performance Compared
Annual Revenue Comparison: Arrowhead Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Amphastar Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Leads in Yearly Revenue?
Revenue Showdown: Travere Therapeutics, Inc. vs Evotec SE